A novel theranostic approach that targets RET -- a newly identified biomarker for neuroendocrine prostate cancer enables high ...

Identification of a predictive factor of metastatic castration-resistant prostate cancer patients’ response to alternative antiandrogen therapy with flutamide. This is an ASCO Meeting Abstract from ...

A new mathematical model which aims to optimise treatment for prostate cancer has been developed by experts at the University of Portsmouth. Prostate cancer is the second most common cancer among men ...

orgovyx (relugolix) is a medicine used to treat advanced prostate cancer in adults. Advanced prostate cancer means that the cancer has spread outside of the prostate. Advanced cancers have often come ...

Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine ...

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...